Hims recaps the year's most surprising health findings, from the growing number of adults who consider monogamy optional to ...

Oza’s new Miami Beach home was built in 1936 and sculpted by architect Lawrence Murray Dixon, who owned it as a personal ...

Hims & Hers is transforming telehealth with personalized medications, rapid subscription growth, and strong financials, ...

Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and ...

Hims & Hers stock price has greatly performed this year as it continued to disrupt the healthcare industry. HIMS has jumped ...

Hims & Hers Health Inc (HIMS) stock saw a decline, ending the day at $26.36 which represents a decrease of $-2.19 or -7.67% from the prior close of $28.55. The stock opened at $26.04 and touched a low ...

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.

Analyst Allen Lutz of Bank of America Securities maintained a Sell rating on Hims & Hers Health (HIMS – Research Report), retaining the ...

NVO is on track for its biggest daily and weekly percentage losses on record, as well as a fourth-straight loss. Shares now ...

Hims & Hers Health (NYSE: HIMS) stock is on a downward trend on both macro trends and news about GLP-1s. But this is still a growth stock investors should watch, which Travis Hoium explains in this ...

BofA notes that yesterday morning, the FDA issued a new decision determining that the shortage of Eli Lilly’s (LLY) tirzepatide was resolved.

It's that time of the year; We all likely indulged more than we'd like to admit for the holidays and put on a few extra ...